HRAS

(redirected from K-RAS)

HRAS

A gene on chromosome 11p15.5 belonging to the Ras oncogene family, the protein products of which bind GTP and GDP, have intrinsic GTPase activity, and play key roles in signal transduction. HRAS cycles between de- and re-palmitoylation, a reaction that regulates its rapid exchange between the plasma membrane and the Golgi apparatus.

Molecular pathology
Defects in HRAS are associated with an increased risk of bladder cancer, Hürthle cell carcinoma of thyroid, and oral squamous cell carcinoma. HRAS mutations cause faciocutaneoskeletal syndrome and congenital myopathy with excess of muscle spindles—a variant of Costello syndrome.
References in periodicals archive ?
Clinical usefulness of K-RAS mutation detection in colorectal cancer and in surgical nargins of the colon.
Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.
K-RAS gene has two alternative forms of exon 4-4A and 4B, which makes the expressed protein produced two forms of K-RAS--4A K-ras and K-ras 4B.
The Phase Ib trial follows the successful completion of a Phase Ia dose escalation study in patients who have B-RAF or K-RAS mutations.
La primera de ellas se denomina supresora o tradicional, que involucra la inactivacion de los genes APC y TP53, la activacion constitutiva del gen K-RAS y, tambien, mutaciones en otros genes.
In addition to this study, we are enrolling patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumors in a U.
K-RAS gene testing for guiding drug choice in metastatic colorectal cancer.
Patients with such K-RAS mutations typically are more resistant to treatment with radiation and have a poor prognosis.
9 measurement, CT, EUS and ERCP to analyse p16, K-RAS and p53 oncogenes, in pancreatic juice.
For example, Pao notes, one study has shown that mutations in a gene called K-RAS makes tumors immune to all the drugs that act on EGFR.
Combinations of MEK and PI3K inhibitors have been tested in models of K-RAS mutant breast, lung and colorectal cancer, and were shown to be superior to single agent treatment (Marte and Downward 1997; Engelman et al.